Connor, Clark & Lunn Investment Management Ltd. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Connor, Clark & Lunn Investment Management Ltd. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$215,422
-39.7%
182,561
-27.9%
0.00%
-50.0%
Q2 2023$357,118
-1.2%
253,275
+5.1%
0.00%0.0%
Q1 2023$361,533
+18.0%
241,022
-8.0%
0.00%0.0%
Q4 2022$306,425
-6.0%
261,902
-9.2%
0.00%0.0%
Q3 2022$326,000
+52.3%
288,299
+113.0%
0.00%
+100.0%
Q2 2022$214,000
+1088.9%
135,328
+1027.7%
0.00%
Q1 2022$18,000
+28.6%
12,000
-17.8%
0.00%
Q3 2020$14,000
-71.4%
14,601
-74.2%
0.00%
Q2 2020$49,000
+16.7%
56,541
+11.5%
0.00%
Q1 2020$42,000
+110.0%
50,718
+129.0%
0.00%
Q4 2019$20,00022,1500.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders